Once daily 3g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis:: A double-blind, double-dummy, randomized, controlled, dose-ranging study

被引：0
|
作者：
Kruis, Wolfgang
Jonaitis, Laimas
Pokrotnieks, Juris
Acute, Gitana
Mikhailova, Tatyana L.
Horynski, Marek
Batovsky, Marian
Racz, Istvan
Kull, Karin
Faszczyk, Mark
Greinwald, Roland
Mueller, Ralph
机构：
来源：
GASTROENTEROLOGY | 2008年 / 134卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A489 / A489
页数：1
相关论文
共 50 条
  • [31] Tramadol Hydrochloride Extended-Release Once-Daily in the Treatment of Osteoarthritis of the Knee and/or Hip: A Double-Blind, Randomized, Dose-Ranging Trial
    DeLemos, Byron P.
    Xiang, Jim
    Benson, Carmela
    Gana, Theophilus J.
    Pascual, Maria Luz G.
    Fleming, R. Rosanna B.
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (03) : 216 - 226
  • [32] Direct Comparison of Two Different Mesalamine Formulations for the Maintenance of Remission in Patients with Ulcerative Colitis: A Double-blind, Randomized Study
    Ito, Hiroaki
    Iido, Mitsuo
    Matsumoto, Tokayuki
    Suzuki, Yasuo
    Aida, Yoshiyuki
    Yoshida, Toyomitsu
    Takano, Yuichi
    Hibi, Toshifumi
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (09) : 1575 - 1582
  • [33] Direct Comparison of Two Different Mesalamine Formulations for the Induction of Remission in Patients with Ulcerative Colitis: A Double-blind, Randomized Study
    Ito, Hiroaki
    Iido, Mitsuo
    Matsumoto, Takayuki
    Suzuki, Yasuo
    Sasaki, Hidetaka
    Yoshida, Toyomitsu
    Takano, Yuichi
    Hibi, Toshifumi
    INFLAMMATORY BOWEL DISEASES, 2010, 16 (09) : 1567 - 1574
  • [34] Effect of montelukast on remission maintenance in patients with ulcerative colitis: a Randomized, double-blind controlled clinical trial
    Shirazi, Kourosh Masnadi
    Diba, Mehran Nezam
    Shirazinezhad, Arman Masnadi
    Nikniaz, Zeinab
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [35] Otilonium bromide in irritable bowel syndrome:A dose-ranging randomized double-blind placebo-controlled trial
    Danuta Chmielewska-Wilkoń
    Giorgio Reggiardo
    Colin Gerard Egan
    World Journal of Gastroenterology, 2014, (34) : 12283 - 12291
  • [36] A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD
    Donohue, James F.
    Anzueto, Antonio
    Brooks, Jean
    Mehta, Rashmi
    Kalberg, Christopher
    Crater, Glenn
    RESPIRATORY MEDICINE, 2012, 106 (07) : 970 - 979
  • [37] Biological activity of Dysport® and Botox® in the human EDB muscle:: A double-blind, randomized, dose-ranging study
    Wohlfarth, Kai
    Schwandt, Imke
    Florian, Wegner
    Juergens, Tim
    Gelbrich, Goetz
    Wagner, Armin
    Bogdahn, Ulrich
    Schulte-Mattler, Wilhelm
    TOXICON, 2008, 51 : 22 - 22
  • [38] BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
    Marcus, Ronald
    Goadsby, Peter J.
    Dodick, David
    Stock, David
    Manos, George
    Fischer, Tanya Z.
    CEPHALALGIA, 2014, 34 (02) : 114 - 125
  • [39] Otilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial
    Chmielewska-Wilkon, Danuta
    Reggiardo, Giorgio
    Egan, Colin Gerard
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (34) : 12283 - 12291
  • [40] A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome
    Bardhan, KD
    Bodemar, G
    Geldof, H
    Schütz, E
    Heath, A
    Mills, JG
    Jacques, LA
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (01) : 23 - 34
12345